Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database

Castillo, Jorge J.; Olszewski, Adam J.; Cronin, Angel M.; Hunter, Zachary; Treon, Steven P.

doi:10.1182/blood-2014-05-574871

Cited by 79 publications

(69 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the OS and the RS improved between the two periods (2000–2006 and 2007–2014), a finding that agrees with other recent studies. Most of the earlier registry studies included LPL/WM; however, our study included only WM (Kristinsson et al , ; Castillo et al , ). Data from previous studies (Kristinsson et al , ) as well as preliminary data from the SLR (unpublished observations) suggest that WM has better survival than LPL.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Brandefors¹,

Melin

Lindh

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

We present a nationwide prospective Swedish registry-based study of Waldenström macroglobulinaemia (WM), that focuses on incidence and survival in relation to clinical prognostic factors and primary systemic therapies. A total of 1511 patients with WM and lymphoplasmocytic lymphoma (LPL) were registered in the Swedish Lymphoma Registry (SLR) between 1 January 2000 and 31 December 2014. The age-adjusted incidence of WM/LPL was 11·5 per million persons per year, three times higher than the reported incidence worldwide. Medical records were retrieved for 1135 patients (75%). A retrospective review showed that 981 (86·1%) of these patients fulfilled the World Health Organization diagnostic criteria for WM and these patients were analysed further. The overall survival (OS) improved between two periods - 2000-2006 and 2007-2014 - with a five-year OS of 61% and 70%, respectively. Significant prognostic factors for OS, evaluated at the time of diagnosis, were age, elevated lactate dehydrogenase level and haemoglobin ≤115 g/l for patients receiving therapy 0-3 months after diagnosis, and age, poor performance status, haemoglobin ≤115 g/l, and female sex in "watch and wait" patients (multivariable analysis). The level of the IgM monoclonal immunoglobulin had no significant prognostic value. Rituximab included in first-line therapy was associated with improved survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Brandefors¹,

Melin

Lindh

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…However, a 20-month improvement in median survival has been noted in patients in the United States SEER database who were diagnosed after the year 2000, and the benefit was evident across all groups except patients below 50 years of age or African Americans [4]. The 5-year relative survival estimates (ratio of the observed survival of WM patients and expected survival of the general population in a specific calendar year) has increased in patients in the United States diagnosed in periods 2001-2005 and 2006-2010 [68]. Similar findings were noted in another Swedish study [69].…”

Section: Prognosismentioning

confidence: 98%

Waldenström macroglobulinemia: What a hematologist needs to know

et al. 2015

View full text Add to dashboard Cite

“…AS605240 has been previously described as an isoform-selective ATP-competitive inhibitor of PI3Kγ [32] while CAL-101 is an oral p110δ inhibitor currently under clinical evaluation in patients with B-cell malignancies [33]. The selective, oral p110δ and p110γ subunits inhibitor, IPI145, is reported to be in phase I study [34]. TGX221, is a p110β-selective inhibitor [35].…”

Section: Introductionmentioning

confidence: 99%

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

et al. 2017

View full text Add to dashboard Cite

B-acute lymphoblastic leukemia (B-ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. Philadelphia chromosome-positive (Ph+) B-ALL is a subtype that expresses the Bcr-Abl fusion protein which represents a negative prognostic factor. Constitutive activation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) network is a common feature of B-ALL, influencing cell growth and survival. In the present study, we aimed to investigate the efficacy of PI3K isoform inhibition in B-ALL cell lines harboring the Bcr-Abl fusion protein.We studied the effects of anti Bcr-Abl drugs Imatinib, Nilotinib and GZD824 associated with PI3K isoform inhibitors. We used a panel of six compounds which specifically target PI3K isoforms including the pan-PI3K inhibitor ZSTK474, p110α BYL719 inhibitor and the dual p110γ/p110δ inhibitor IPI145. The effects of single drugs and of several drug combinations were analyzed to assess cytotoxicity by MTS assays, apoptosis and autophagy by flow cytometry and Western blot, as well as the phosphorylation status of the pathway.ZSTK474, BYL719 and IPI145 administered in combination with imatinib, nilotinib and GZD824 for 48 h, decreased cell viability, induced apoptosis and autophagy in a marked synergistic manner.These findings suggest that selected PI3K isoform inhibitors used in combination with anti Bcr-Abl drugs may be an attractive novel therapeutic intervention in Ph+ B-ALL.

show abstract

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database

Cited by 79 publications

References 8 publications

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Waldenström macroglobulinemia: What a hematologist needs to know

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

Contact Info

Product

Resources

About